Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.62 |
| ▸ | ACHE | P22303 | 2/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | BACE1 | P56817 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23501029 | 0.91 | SIGMAR1 (0.57) | HRH3ACHESIGMAR1SMN1; SMN2BACE1 | |
| SCHEMBL29201740 | 0.88 | ACHE (0.62) | HRH3ACHESIGMAR1SMN1; SMN2BACE1 | |
| SCHEMBL2390775 | 0.84 | MEN1 (0.68) | HRH3ACHESIGMAR1SMN1; SMN2BACE1 | |
| SCHEMBL14198699 | 0.82 | MAPT (0.67) | SIGMAR1MEN1KMT2A | |
| SCHEMBL7375679 | 0.82 | SIGMAR1 (0.65) | ACHESIGMAR1 | |
| SCHEMBL8320248 | 0.82 | HRH3 (0.69) | HRH3ACHESIGMAR1SMN1; SMN2BACE1 | |
| SCHEMBL12504038 | 0.82 | HRH3 (0.56) | HRH3ACHESMN1; SMN2MEN1KMT2A | |
| SCHEMBL7801432 | 0.82 | SIGMAR1 (0.56) | ACHESIGMAR1SMN1; SMN2BACE1MEN1 | |
| SCHEMBL1043952 | 0.81 | SIGMAR1 (0.85) | SIGMAR1SMN1; SMN2 | |
| SCHEMBL20804352 | 0.81 | SIGMAR1 (0.85) | SIGMAR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2603098-B1 | METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER | FIRMENICH INCORPORATED (US) | 2025-08-06 | — | — | EP | disclosed |
| US-11129397-B2 | Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer | FIREMENICH INCORPORATED (US) | 2021-09-28 | — | — | US | disclosed |
| EP-3484879-B1 | HYDROXYQUINOLINONE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2020-12-30 | — | — | EP | disclosed |
| CN-106107406-B | Methods of improving the stability of sweetness enhancers and compositions comprising stable sweetness enhancers | 弗门尼舍公司 | 2020-06-09 | — | — | CN | disclosed |
| EP-2552207-B1 | SWEET FLAVOR MODIFIER | FIRMENICH INCORPORATED (US) | 2019-08-21 | — | — | EP | disclosed |
| US-20190208802-A1 | METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER | FIRMENICH INCORPORATED | 2019-07-11 | — | — | US | disclosed |
| US-10244779-B2 | Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer | SENOMYX, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-10196386-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-02-05 | — | — | US | disclosed |
| US-9902737-B2 | Sweet flavor modifier | SENOMYX, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| WO-2018011090-A1 | HYDROXYQUINOLINONE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-01-18 | — | — | WO | disclosed |
| CN-102933081-A | Sweet flavor modifier | SENOMYX INC | 2013-02-13 | — | — | CN | disclosed |
| EP-2552207-A1 | SWEET FLAVOR MODIFIER | Senomyx, Inc. (US) | 2013-02-06 | — | — | EP | disclosed |
| US-8236805-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2012-08-07 | — | — | US | disclosed |
| WO-2012021837-A2 | METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER | SENOMYX, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
| US-20120041078-A1 | METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER | SENOMYX, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2011123693-A1 | SWEET FLAVOR MODIFIER | SENOMYX, INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| US-20110245353-A1 | SWEET FLAVOR MODIFIER | SENOMYS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-7700597-B2 | Substituted piperazines as CB1 antagonists | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-7659275-B2 | treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis | SCHERING CORPORATION (US) | 2010-02-09 | — | — | US | disclosed |
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | SCHERING CORPORATION | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10244779-B2 | Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer | TFEB, TREH, SLC2A8 | HRH3 3564/4885ACHE 3500/4885SIGMAR1 3543/4885 |
| US-20120041078-A1 | METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER | TFEB, TREH, SLC2A8 | HRH3 3564/4885ACHE 3500/4885SIGMAR1 3543/4885 |
| US-20110245353-A1 | SWEET FLAVOR MODIFIER | TAS2R5, TAS2R10, TAS2R50 | HRH3 2670/4885ACHE 1061/4885SIGMAR1 1597/4885 |
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | CNR1, CNR2, GPR119 | HRH3 932/4885ACHE 1257/4885SIGMAR1 114/4885 |
| US-11129397-B2 | Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer | TFEB, TREH, SLC2A8 | HRH3 3564/4885ACHE 3500/4885SIGMAR1 3543/4885 |
| US-10196386-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2B | HRH3 164/4885ACHE 374/4885SIGMAR1 193/4885 |
| US-20190208802-A1 | METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER | TFEB, TREH, SLC2A8 | HRH3 3564/4885ACHE 3500/4885SIGMAR1 3543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.